TMCI Quote, Financials, Valuation and Earnings

Retractable Technologies has a net margin of -34.07% compared to Treace Medical Concepts's net margin of -18.58%. Treace Medical Concepts's return on equity of -49.68% beat Retractable Technologies's return on equity of -16.83%.

Treace Medical Concepts has a consensus price target of $7.96, signalling upside risk potential of 14.2%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Treace Medical Concepts has higher upside potential than Retractable Technologies, analysts believe Treace Medical Concepts is more attractive than Retractable Technologies.

Treace Medical Concepts has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

Treace Medical Concepts has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

Treace Medical Concepts quarterly revenues are $45.1M, which are larger than Retractable Technologies quarterly revenues of $10.3M. Treace Medical Concepts's net income of -$15.4M is lower than Retractable Technologies's net income of -$1.9M. Notably, Treace Medical Concepts's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts is 2.13x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of -34.07% compared to Treace Medical Concepts's net margin of 15.18%. Treace Medical Concepts's return on equity of -49.68% beat Stryker's return on equity of 18.78%.

Treace Medical Concepts has a consensus price target of $7.96, signalling upside risk potential of 14.2%. On the other hand Stryker has an analysts' consensus of $406.60 which suggests that it could grow by 9.66%. Given that Treace Medical Concepts has higher upside potential than Stryker, analysts believe Treace Medical Concepts is more attractive than Stryker.

Treace Medical Concepts has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stryker has a beta of 0.938, suggesting its less volatile than the S&P 500 by 6.217%.

Treace Medical Concepts has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.86% to investors and pays a quarterly dividend of $0.80 per share. Treace Medical Concepts pays -- of its earnings as a dividend. Stryker pays out 35.99% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Treace Medical Concepts quarterly revenues are $45.1M, which are smaller than Stryker quarterly revenues of $5.5B. Treace Medical Concepts's net income of -$15.4M is lower than Stryker's net income of $834M. Notably, Treace Medical Concepts's price-to-earnings ratio is -- while Stryker's PE ratio is 39.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts is 2.13x versus 6.50x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -34.07% compared to Treace Medical Concepts's net margin of -4291.67%. Treace Medical Concepts's return on equity of -49.68% beat Catheter Precision's return on equity of -65.84%.

Treace Medical Concepts has a consensus price target of $7.96, signalling upside risk potential of 14.2%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 429.24%. Given that Catheter Precision has higher upside potential than Treace Medical Concepts, analysts believe Catheter Precision is more attractive than Treace Medical Concepts.

Treace Medical Concepts has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

Treace Medical Concepts has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Treace Medical Concepts quarterly revenues are $45.1M, which are larger than Catheter Precision quarterly revenues of $96K. Treace Medical Concepts's net income of -$15.4M is lower than Catheter Precision's net income of -$4.1M. Notably, Treace Medical Concepts's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts is 2.13x versus 1.01x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -34.07% compared to Treace Medical Concepts's net margin of -17.98%. Treace Medical Concepts's return on equity of -49.68% beat Xtant Medical Holdings's return on equity of -35.98%.

Treace Medical Concepts has a consensus price target of $7.96, signalling upside risk potential of 14.2%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than Treace Medical Concepts, analysts believe Xtant Medical Holdings is more attractive than Treace Medical Concepts.

Treace Medical Concepts has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Treace Medical Concepts has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Treace Medical Concepts pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Treace Medical Concepts quarterly revenues are $45.1M, which are larger than Xtant Medical Holdings quarterly revenues of $27.9M. Treace Medical Concepts's net income of -$15.4M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Treace Medical Concepts's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Treace Medical Concepts is 2.13x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.